Riskpilot← Back to searchSign inGet full accessExini Diagnostics Aktiebolag
ABActiveOrg 5565761995Scheelevägen 27Computer programming activities · NACE 6210Est. 199914 employees
Revenue 2024
SEK 48,2M
+16% vs 2023
EBITDA margin
6.7%
+811% vs 2023
Equity ratio
17.2%
Financial strength
Net profit 2024
SEK 3M
+3023% vs 2023
| Revenue | SEK 48,2M | +16% |
| EBITDA | SEK 3,2M | +811% |
| Net profit | SEK 3M | +3023% |
| Total assets | SEK 38,1M | +75% |
| Equity | SEK 6,6M | +83% |
| Employees | 14 | — |
Legal name
Exini Diagnostics Aktiebolag
Org number
5565761995
Legal form
Aktiebolag
NACE code
6210 · Computer programming activities
Founded
29 september 1999
Share capital
SEK 1 838 000
Employees
14 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva utveckling av program för automatisk analys av medicinska data som erbjuder läkare diagnostiska råd, konsultverksamhet i anslutning härtill, äga och förvalta värdepapper och fast egendom samt därmed förenlig verksamhet.
Address
Scheelevägen 27
Phone
+46462865420
Email
info@exini.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 277 | 22 674 | 11 687 | 41 669 | 48 197 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −24 308 | −1 243 | −22 765 | 355 | 3 234 |
| Depreciation & amort. | −493 | −488 | −439 | −450 | −458 |
| EBIT | −24 801 | −1 731 | −23 204 | −95 | 2 776 |
| Net financials | −2 | −1 | −19 | 190 | 191 |
| Profit before tax | −24 803 | −1 732 | −23 223 | 95 | 2 967 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −24 803 | −1 732 | −23 223 | 95 | 2 967 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 17 619 | 16 179 | 14 015 | 21 716 | 38 100 |
| Equity | 13 454 | 11 722 | 3 498 | 3 593 | 6 560 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 165 | 4 457 | 10 517 | 18 123 | 31 540 |
| Total debt | 4 165 | 4 457 | 10 517 | 18 123 | 31 540 |
EBITDA margin
6.7%
This company
15.8%
Market median
-58% vs market
20202024
Equity ratio
17.2%
This company
38.2%
Market median
-55% vs market
20202024
Return on equity
45.2%
This company
18.4%
Market median
+146% vs market
20202024
Net profit margin
6.2%
This company
8.1%
Market median
-23% vs market
20202024
Asset turnover
1.27×
This company
1.12×
Market median
+13% vs market
20202024
Debt / equity
4.81×
This company
0.62×
Market median
-676% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GT Chief Auditor | Chief Auditor | 2022 |
| Former (1) | ||
AC | Audit | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2024 | |
| Chairman | 2026 | |
| Former (2) | ||
| Chairman | 2021 – 2024 | |
| Chairman | 2020 – 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PROGENICS PHARMACEUTICALS INC
Exini Diagnostics Aktiebolag (this company)Board members of Exini Diagnostics Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ann Charlotte Theander | Audit | 0 companies |
| Gunvor Therése Henningsson | Chief Auditor | 0 companies |
| Aseem Undvall Anand | Board of Directors | 0 companies |
| Etienne Montagut | Chairman | 0 companies |
| Eva Marianne Voss | Deputy Board Member | 0 companies |
| Mark Robert Baker | Chairman | 0 companies |
| Jens Filip Andreas Richter | Chairman | 0 companies |